Mandate

Vinge advises ITAB in connection with a recapitalisation of SEK 868 million

February 11, 2021 Capital Markets and Public M&A

The recapitalisation is carried out to strengthen ITAB’s capital structure to reduce the financial leverage of the group, to invest in the One ITAB transformation plan and to provide sufficient headroom to the business given the Covid-19 situation.

The recapitalisation entails that the equity is strengthened by approx. SEK 868 million by a rights issue of SEK 768 million and a set-off issue of SEK 100 million and entails further that Aeternum Capital becomes ITAB’s largest shareholder with a holding of approx. 25 percent of the shares. First day of trading in the new class B shares issued as a result of the recapitalisation is estimated to be 22 March 2021.

ITAB sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The offer includes custom-made fitting concepts, innovative solutions for the checkout area, professional lighting systems and interactive products. Customers include major retail chains throughout most of Europe. ITAB’s class B shares are listed on Nasdaq Stockholm.

Vinge’s team mainly consisted of Charlotte Levin, Rikard Lindahl, Annika Nyberg Ekenberg, Clara Sohlberg, Mikaela Falkner, Henrik Wastenson and David Bokliden.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025